DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Information source: Eisai Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Idiopathic Thrombocytopenic Purpura (ITP)

Intervention: E5501 (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Eisai Inc.

Official(s) and/or principal investigator(s):
Gina Pastino, Study Director, Affiliation: Eisai Inc.


36 healthy adult men and women will be enrolled with the goal of having 24 subjects complete the entire study. The study will consist of a pre-treatment phase and a treatment phase. The pre-treatment phase will include screening and baseline period 1. The treatment phase

consists of 4 treatment period: Treatment Period 1 - administration of the first E5501 oral

dose; Treatment Period 2 - administration of verapamil and the second E5501 oral dose;

Treatment Period 3 - administration of the third E5501 dose; Treatment Period 4 -

concomitant administration of cyclosporine and the fourth E5501 dose. A baseline period will precede each treatment period. The screening period will be up to 13 days in duration. After

fulfilling screening requirements, subjects will check into the clinic on Day - 1 for

baseline assessments. They will be domiciled in the clinical testing facility for 6 days for Treatment Periods 1, 3, and 4 and will return intermittently for study procedures for 8 outpatient visits. They will be domiciled in the clinical testing facility for at least 14 days for Treatment Period 2 and will return intermittently for study procedures for 7 outpatient visits.

Clinical Details

Official title: An Open-label, Single-sequence, Four-treatment Period Study to Evaluate Pharmacokinetic and Pharmacodynamic Interactions Between E5501 and Verapamil, and E5501 and Cyclosporine, Known P-glycoprotein Inhibitors in Healthy Subjects

Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Plasma concentrations of E5501

Secondary outcome: Platelet counts


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.



- Healthy adult men and women (age 18 to 55 years)

- Body mass index greater than or equal to 18kg/m2 and less than or equal to 32kg/m2 at

the time of Screening and at each Baseline

- Platelet count between 120x109/L and 300x109/L at Baseline

- Women of childbearing potential must agree to use a highly effective method of

contraception, other than estrogen-based hormonal contraceptives, during the treatment phase of the study Exclusion:

- Evidence of clinically significant cardiovascular, hepatic, gastrointestinal, renal,

respiratory, endocrine, hematologic, neurologic, or psychiatric disease or abnormalities or a known history of any gastrointestinal surgery that could impact the PK of the study

- Agents associated with thrombotic events (including oral contraceptives) must be

discontinued within 30 days of first study drug administration

- Evidence of organ dysfunction or any clinically significant event or illness in the

subject's medical history, e. g., history of splenectomy

- History of arterial or venous thrombosis, including partial or complete thromboses

(e. g., stroke, transient ischemic attack, myocardial infarction, deep vein thrombosis, or pulmonary embolism). Known family history of hereditary thrombophilic disorders (e. g., Factor V Leiden, antithrombin III deficiency, etc.)

- Hemoglobin less than the lower limit of normal levels (women, 7. 1 mmol/L; men, 8. 1

mmol/L) In addition, other standard criteria for healthy volunteers will be used.

Locations and Contacts

Celerion, Tempe, Arizona 85283, United States
Additional Information

Starting date: September 2011
Last updated: May 18, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017